Diminished ovarian reserve – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:16:20 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Diminished ovarian reserve – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Effects of Low Dose Choriogonadotropin Alfa in Women with Diminished Ovarian Reserve Undergoing IVF/ICSI https://clinicaltrials.eu/trial/study-on-the-effects-of-low-dose-choriogonadotropin-alfa-in-women-with-diminished-ovarian-reserve-undergoing-ivf-icsi/ Wed, 29 Apr 2026 15:05:08 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-low-dose-choriogonadotropin-alfa-in-women-with-diminished-ovarian-reserve-undergoing-ivf-icsi/ This clinical trial is focused on studying a condition known as diminished ovarian reserve, which is a cause of infertility in women. The study will explore the effects of a treatment called low dose hCG priming in women undergoing IVF/ICSI (in vitro fertilization/intracytoplasmic sperm injection). The medication used in this study is called Ovitrelle, which contains the active substance choriogonadotropin alfa. This trial will compare the effects of this medication with a placebo to see if it can help increase the number of eggs retrieved during the IVF/ICSI process.

The purpose of the study is to examine whether using low dose hCG priming for eight weeks can improve outcomes for women with diminished ovarian reserve who are undergoing IVF/ICSI. The study will last for a period of time during which participants will receive either the medication or a placebo. The main focus will be on the number of eggs retrieved, but other factors such as the number of fertilized eggs, embryo quality, and pregnancy rates will also be observed.

Participants will receive the treatment through a subcutaneous injection, which means the medication is injected under the skin. The study aims to confirm findings from a previous pilot study that suggested a significant increase in the number of eggs retrieved could be achieved with this treatment. The trial will help determine if this approach can be beneficial for women facing challenges with fertility due to diminished ovarian reserve.

]]> Study on the Safety and Effectiveness of Platelet Concentrate for Women with Low Ovarian Reserve https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-platelet-concentrate-for-women-with-low-ovarian-reserve/ Wed, 29 Apr 2026 14:22:43 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-platelet-concentrate-for-women-with-low-ovarian-reserve/ This clinical trial is focused on studying a condition known as Low Ovarian Reserve, which affects some women’s ability to conceive. The treatment being tested is called Plasma Rich in Growth Factors, also known as Platelet Rich Plasma Human. This treatment involves using a special preparation made from blood components, which is injected into the ovaries to potentially improve their function.

The purpose of the study is to evaluate the safety and effectiveness of this treatment in women with low ovarian reserve. Participants will receive injections of the plasma rich in growth factors, and their ovarian function will be monitored before and after the treatment. This includes checking various markers of ovarian health and observing the outcomes of any fertility treatments they may undergo, such as in vitro fertilization (IVF).

Throughout the study, researchers will compare the participants’ ovarian health markers and fertility treatment results before and after receiving the plasma injections. This will help determine if the treatment can improve the chances of pregnancy and the quality of embryos. The study will also track any complications related to pregnancy that may arise after the treatment. The trial is expected to continue until 2026, providing valuable insights into the potential benefits of this innovative approach for women with low ovarian reserve.

]]>